Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 4/2018

01-08-2018 | Commentary

Pharmacovigilance in developing countries (part II): a path forward

Authors: Shaimaa Elshafie, Anne Marie Roberti, Iman Zaghloul

Published in: International Journal of Clinical Pharmacy | Issue 4/2018

Login to get access

Abstract

In recent years, attention to pharmacovigilance has gained momentum in developing countries, however awareness of, and policies or systems for pharmacovigilance in most developing countries still lags sharply behind developed countries. This article proposes different strategies to encourage the introduction and sustain the advancement of robust pharmacovigilance systems in developing countries. To this end, this article seeks to accomplish the ultimate goal of pharmacovigilance in a developing country context; ensuring patient safety and promoting safe and rational use of drugs.
Literature
2.
go back to reference Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Strategies to improve adverse drug reaction reporting: a critical and systematic review. Drug Saf. 2013;36(5):317–28.CrossRef Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Strategies to improve adverse drug reaction reporting: a critical and systematic review. Drug Saf. 2013;36(5):317–28.CrossRef
3.
go back to reference Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis. Drug Saf. 2010;33:689–703.CrossRef Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis. Drug Saf. 2010;33:689–703.CrossRef
4.
go back to reference Pagotto C, Varallo F, Mastroianni P. Impact of educational interventions on adverse drug events reporting. Int J Technol Assess Health Care. 2013;29(4):410–7.CrossRef Pagotto C, Varallo F, Mastroianni P. Impact of educational interventions on adverse drug events reporting. Int J Technol Assess Health Care. 2013;29(4):410–7.CrossRef
5.
go back to reference Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited countries. Expert Rev Clin Pharmacol. 2015;8:449–60.CrossRef Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited countries. Expert Rev Clin Pharmacol. 2015;8:449–60.CrossRef
6.
go back to reference Shankar PR, Subish P, Mishra P, Dubey AK. Teaching pharmacovigilance to medical students and doctors. Ind J Pharmacol. 2006;38(5):316–9.CrossRef Shankar PR, Subish P, Mishra P, Dubey AK. Teaching pharmacovigilance to medical students and doctors. Ind J Pharmacol. 2006;38(5):316–9.CrossRef
7.
go back to reference Van Hunsel F, Härmark L, Pal S, Olsson S, van Grootheest K. Experiences with adverse drug reaction reporting by patients: an 11-country survey. Drug Saf. 2012;35(1):45–60.CrossRef Van Hunsel F, Härmark L, Pal S, Olsson S, van Grootheest K. Experiences with adverse drug reaction reporting by patients: an 11-country survey. Drug Saf. 2012;35(1):45–60.CrossRef
8.
go back to reference Jha N, Rathore DS, Shankar PR, Thapa BB, Bhuju G, Alshakka M. Need for involving consumers in Nepal’s pharmacovigilance system. Aust Med J. 2014;7(4):191–5.CrossRef Jha N, Rathore DS, Shankar PR, Thapa BB, Bhuju G, Alshakka M. Need for involving consumers in Nepal’s pharmacovigilance system. Aust Med J. 2014;7(4):191–5.CrossRef
11.
go back to reference Kuchya S, Kalaiselvan V, Kaur I, Singh GN. Mobile application an approach to enhance easy adverse drug reactions reporting in India. Health Technol. 2016;6(2):157–8.CrossRef Kuchya S, Kalaiselvan V, Kaur I, Singh GN. Mobile application an approach to enhance easy adverse drug reactions reporting in India. Health Technol. 2016;6(2):157–8.CrossRef
14.
go back to reference Edwards IR, Lindquist M. Social media and networks in pharmacovigilance: boon or bane? Drug Saf. 2011;34(4):267–71.CrossRef Edwards IR, Lindquist M. Social media and networks in pharmacovigilance: boon or bane? Drug Saf. 2011;34(4):267–71.CrossRef
21.
go back to reference Jeetu G, Anusha G. Pharmacovigilance: a worldwide master key for drug safety monitoring. J Young Pharm. 2010;2(3):315–20.CrossRef Jeetu G, Anusha G. Pharmacovigilance: a worldwide master key for drug safety monitoring. J Young Pharm. 2010;2(3):315–20.CrossRef
25.
go back to reference Riviere JE, Buckley GJ. Ensuring safe foods and medical products through stronger regulatory systems abroad. Washington (DC): Institute of Medicine of the National Academies Press (2012). Accessed Oct 2016. Riviere JE, Buckley GJ. Ensuring safe foods and medical products through stronger regulatory systems abroad. Washington (DC): Institute of Medicine of the National Academies Press (2012). Accessed Oct 2016.
28.
go back to reference Pirmohamed M, Atuah KN, Dodoo AN, Winstanley P. Pharmacovigilance in developing countries. BMJ. 2007;335(7618):462.CrossRef Pirmohamed M, Atuah KN, Dodoo AN, Winstanley P. Pharmacovigilance in developing countries. BMJ. 2007;335(7618):462.CrossRef
29.
go back to reference Babigumira JB, Stergachis A, Choi HL, Dodoo A, Nwokike J, Garrison LP Jr. A framework for assessing the economic value of pharmacovigilance in low- and middle-income countries. Drug Saf. 2014;37(3):127–34.CrossRef Babigumira JB, Stergachis A, Choi HL, Dodoo A, Nwokike J, Garrison LP Jr. A framework for assessing the economic value of pharmacovigilance in low- and middle-income countries. Drug Saf. 2014;37(3):127–34.CrossRef
Metadata
Title
Pharmacovigilance in developing countries (part II): a path forward
Authors
Shaimaa Elshafie
Anne Marie Roberti
Iman Zaghloul
Publication date
01-08-2018
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 4/2018
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-017-0588-2

Other articles of this Issue 4/2018

International Journal of Clinical Pharmacy 4/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.